Company Profile: Creso Pharma Ltd (ASX: CPH) is a cannabis sector company that can deliver products with standardised dosing and formulations. It follows Good Manufacturing Practices (GMP) standards. The key aim is to deliver pharmaceutical expertise with delivery of highest quality products in the cannabis space. In this regard, therapeutic-grade Nutraceuticals that have been derived from hemp is another class of products that the group is working on. The group is developing presence in many markets and aims to offer a diverse portfolio of solutions across the globe. The products developed belong to categories ranging from Therapeutics, Animal health, nutraceuticals, topicals and lifestyle.
Start discussion with value Investors for ASX Stock Market Investment and Opinion.
Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s
Those phrases have become increasingly common as marijuana legalization spreads.
Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500. Click here for your FREE Report